Clinical applications of radioprotectors

References

• Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin. Oncol 26, 3–21 (1999).
   PubMed Web of Science ®Google Scholar
• •An excellent broad review of the basic research on amifostine, with explanation of its mechanism of action.
   Google Scholar
• Lindegaard JC, Grau C. Has the outlook improved for amifostine as a clinical radioprotector? Racliother. awl 57, 113–118 (2000).
   Google Scholar
• Liu T, Liu Y, HE S, Zhang Z, Kligerman MM. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer69, 2820–2825 (1992).
   Google Scholar
• ••The first randomized trial of amifostine inradiation therapy, proving the principle of normal tissue protection in a controlled design study.
   Google Scholar
• Kemp G, Rose P, Lurain J et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized controlled trial in patients with advanced ovarian cancer. j Clin. Oncol 5, 574–578 (1987).
   PubMedGoogle Scholar
• ••Landmark study, which led to the firstFDA approval of amifostine as a chemoprotectant.
   Google Scholar
• Brizel DM, Wasserman TH, Henke M et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Clin. 0=1 18, 3339–3345 (2000).
   Google Scholar
• ••The pivotal study, which led to the FDAapproval of amifostine as a first radioprotectant, to be applied in head and neck cancer patients.
   Google Scholar
• Buentzel J, Kuttner K, Frohlich D, Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann. Oncol 9, 505–509 (1998).
   PubMedGoogle Scholar
• ••The first trial to apply amifostine in acombined modality therapy with only twice-weekly novel dosing scheme.
   Google Scholar
• Antonadou D, Synodinou M, Boufi M, Sagriotis A, Paloudis S, Throuvalas N. Amifostine reduces acute toxicity during radiochemotherapy in patients with localized advanced stage non-small cell lung cancer. Pox. Am Soc. Clin. awl 19, 501a (2000).
   Google Scholar
• •One of two randomized trials suggesting a beneficial effect of amifostine on treatment-related esophagitis.
   Google Scholar
• Antonadou D, Coliarakis N, Synodinou M et al. Randomized Phase III trial of radiation ± amifostine in patients with advanced stage lung cancer. Int. j Racliat. awl Biol. iiyc. 45, 154 (1999).
   Google Scholar
• •One of two randomized trials suggesting a beneficial effect of amifostine on treatment-related esophagitis.
   Google Scholar
• Komaki R, Lee JS, Kaplan B et al Randomized Phase III study of chemoradiation ± amifostine in patients with inoperable stage II—III non-small cell lung cancer (NscLq . Proc. Am Soc. Clin. awl 20, #1298 (2001).
   Google Scholar
• Kligerman MM, Turrisi AT, Urtasun RC, Norfleet AL, Phillips TL, Barkley T Final report on Phase I trial of WR-2721 before protracted fractionated radiation therapy. Int. Racliat. Oncol Biol. Phys. 14, 1119–1122 (1998).
   Google Scholar
• •The landmark Phase I trial, which established a maximally tolerated dose of amifostine for daily fractionated radiation therapy.
   Google Scholar
• Calhoun EA, Bennett CL. Pharmacoeconomics of amifostine in oncology. ONE2, 25–28 (2000).
   Google Scholar
• Longo CJ. Choices of methodology in pharmacoeconomics studies. Merl Care A532-5 (1999).
   Google Scholar
• Dranitsaris G. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of maifostine cytoprotection. Support. Cate Cancer5, 489–499 (1997).
   PubMed Web of Science ®Google Scholar
• Bennett CL, Lane D, Stinson T, Glatzel M, Buentzel J. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized Phase II clinical trial from Germany. Cancer Invest. 19, 107–113 (2001).
   PubMed Web of Science ®Google Scholar
• Byhardt RVV, Scott C, Sause WT eta]. Response, toxicity, failure patterns and survival in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. int. j Racliat. Oncol Biol. fiyc. 42, 469–478 (1998).
   Google Scholar
• Vokes EE, Leopold IKA, Herndon JE et al. A randomized Phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer (NscLq. Proc. Am. Soc. Clin. Oncol 18, 459a (1999).
   Google Scholar
• Curran WJ, Scott C, Langer C et al. Phase III comparison of sequential vs. concurrent chemoradiotherapy for patients with unresected stage III non-small cell lung
   Google Scholar
• •• cancer: Initial report of RTOG 9410. Bor. Am. Soc. Clin. amyl 19, 484a (2000).
   Google Scholar
• •A major cooperative group trial indicating superiority of concurrent versus sequential chemoradiotherapy for lung cancer.
   Google Scholar
• Furuse K, Fukuoka M, Takada Y et al. Phase III study of concurrent vs. sequential thoracic radiotherapy (TRT) in combination with mitomycin (M), vindesina (V) and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC): five-year median follow-up results. Proc. Am. Soc. Clin. amyl 18, 458a (1999).
   Google Scholar
• Choy H, Akerley W, Safran H et al. Multiinstitutional Phase II trial of paclitaxel carboplatin and concurrent radiation therapy for locally advanced non-small cell lung cancer. 1 Clin. °Tirol 16, 3316–3322 (1998).
   Google Scholar
• Werner-Wasik M, Pequignot E, Leeper D, Hauck W Curran W Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: A multivariate analysis of patients with lung cancer treated with non-operative therapy. int. j Racliat. awl Biol. iiy. 48, 689–696 (2000).
   Google Scholar
• •One of three multivariate analyses of acute esophagitis, suggesting that length of esophagus in the RT field is not related to the severity of esophagitis.
   Google Scholar
• Choy H, LaPorte K, Knill-Selby E et al Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin. Racliat. amyl 90, 96 (1999).
   Google Scholar
• Werner-Wasik M, Scott C, Graham ML et al Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients. Int. j Radiat. Oncol Biol. Phys. 44, 327–331 (1999).
   Google Scholar
• Werner-Wasik M, Axelrod SA, Friedland DP eta]. Preliminary report on reduction of esophagitis by amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy. Clin. Lung Cancer 2, 284–289 (2001).
   Google Scholar
• •A Phase II study, which provided impetus for the design of an ongoing Phase III RTOG trial testing the usefulness of amifostine in esophagitis prevention.
   Google Scholar
• Stickle RL, Epperly MW Klein E eta]. Prevention of irradiation-induced esophagitis by plasmidiliposome delivery of the human manganese superoxide dismutase transgene. Radiat. Oncol Invest. 7, 204–217 (1999).
   Google Scholar
• Wang J, Zheng H, Sung CC, Hauer-Jensen M. The synthetic somatostatin analogue, octreotide, ameliorates acute and delayed intestinal radiation injury. int. j Racliat. Oncol Biol. fiyc. 45, 1289–1296 (1999).
   Google Scholar
• Huang EY, Leung SW Wang CJ et al Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int. Racliat. Oncol Biol. fiyc. 46, 535–539 (2000).
   PubMed Web of Science ®Google Scholar
• Spielberegr RT, Stiff B, Emmanouilides C et al. Efficacy of recombinant human keratinocyte growth factor in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation after radiation-based conditioning: Results of a Phase II trial. Proc. Am. Soc. Clin. Oncol 20, 7a(#25) (2001).
   Google Scholar
• Tannehill SP, Mehta MP, Larson M et al. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small cell lung cancer: results of a Phase II trial.j Clin. °Tirol 15, 2850–2857 (1997).
   PubMedGoogle Scholar
• Bourhis J, De Crevoisier R, Abdulkarim B et al A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int. .1. Racliat. Oncol Biol. Phyc. 46, 1105–1108 (2000).
   Google Scholar
• Shaw L, Brown W, Schein P, Stogniew M. A Phase I study comparing the relative bioavailability of intravenous and subcutaneous administration of amifostine (Ethyol). Proc. Am. Soc. Clin. Oncol 16, 250a (1997).
   Google Scholar
• •A preclinical study, which demonstrated that subcutaneous amifostine has good bioavailability and can be used in the clinic.
   Google Scholar
• Koukourakis MI, Kyrias G, Kakolyris S et al Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized Phase II study. j Clin. Oncol 18, 2226–2233 (2000).
   PubMed Web of Science ®Google Scholar
• ••A major study of the application ofamifostine in the clinic.
   Google Scholar
• Livesey JC, Wiens LW, Von Seggern DJ, Barlow WE, Arnold AM. Inhibition of radiation cataractogenesis by WR-77913. Racliat. Res. 141, 99–104 (1995).
   Google Scholar
• Bhatia S, Robison L, Oberlin 0, Meadows AT Second malignant neoplasms following childhood Hodgkin's disease: Follow-up of the Late Effects Study Group cohort. Proc. Am. Soc. Clin. Oncol 14, 409 (1995).
   Google Scholar
• Kataoka Y, Perrin J, Hunter N, Milas L, Grdina DJ. Antimutagenic effects of amifostine: Clinical inplications. Semin. Oncol 23, 53–57 (1996).
   Google Scholar